Jennifer Bath: So yes, I’m happy to answer that. That’s very observant on your part for our product sales year-over-year. And so a couple of clarifications on that when we break down and look a little bit more closely at our product sales. So the Wnt protein is actually our best selling off-the-shelf product coming from our Utrecht facility. And as mentioned by Barry, it is something that we have exclusivity to an IP protection around. So Wnt protein is interesting in the sense that our primary buyers for that protein are ones who are seeking to include that in growth media for these organoids and also large scale contracts to be able to turn around and actually resell the Wnt protein. So that needs to, in those particular cases, be bought in bulk, so that they can be sold competitively still on the market.
With regard to any sort of decrease in product sales, that’s because when we provide our product sales numbers, we actually do it, just on a consolidated basis across all of our sites across the globe. And we do have a particular product that historically has had a couple of large product sales out of our site in Oss in the Netherlands. And as of this year, the group that routinely places an order for that particular product has not yet placed an order, even though we still anticipate them to do so because they’ve been a regular client. So the dip is actually not something that pertains directly to the Wnt protein. And so going forward, we actually do anticipate that Wnt protein to take over more and more a significant share of the off-the-shelf product.
And that’s in part, because what we’re beginning to see is more and more groups wanting to be able to come in and get access to that Wnt protein because of the quality of that protein, the stability of the protein, and the increased activity of that Wnt surrogate protein reported by several different larger technology companies compared to some of the standard Wnt proteins that are otherwise available on the market.
Swayampakula Ramakanth: Perfect. Thanks. Thanks for breaking down that product sales. What is there in the product sales? So one final question from me before I step down. In terms of the tau we see, it’s obviously very encouraging to see able to neutralize even the latest mutant of the virus. How are €“ if this, how big of a commercial opportunity do you think this is, especially when you would be coming into the market, at least two years down the line, if not more. And with the virus mutating all the time, do you think the structure of your antibody is such that it can capture whatever mutants comes down the pike? So that’s one question. And the other question is on the oncology offerings, are those more for you to out license? Or are these products more for similar to what you’re doing with TATX in the sense at least initiate data, and then, go to the market for out license?
Jennifer Bath: Okay. Yes, so starting first of all with the PolyTope program. So I think one of the first things to always cover is the fact that we absolutely don’t see SARS-CoV-2 going anywhere. Just based on the science and what we know about virus evolution and its ability to continue to adapt. With regard to the relevance of our PolyTope, we actually believe that we’re in a better position than we ever could have. We were €“ so I think specific from the beginning and saying, we are not going to be the first out there. But our intent is obviously to build something that has sustainable efficacy. So that eventually when we predict others will need to go back to the drawing board, because they will lose efficacy, that we will retain that efficacy and eventually take a pole position in the market because we never had to go back and reset our timelines and reset our strategy.
And so today, and kind of going back, real quick to one of the things that Ilse mentioned here we are sitting in working groups with these large pharmaceutical companies that did get products out there that did have commercialized products with emergency use authorization. Many of the products that only lasted a couple of months actually in that commercial setting. And then were no longer efficacious due to these mutations. And last, obviously, the regulatory approval. And so had relatively short timeframe with regard to commercial benefits. From our perspective, the probability of our program, of our products staying efficacious and having a much longer-term window in a commercial setting is probable. And the reason why we say that is because we have all of our historical data and based also on the scientific way that we actually constructed PolyTope.
It was actually designed to do exactly that. So we are at this point in time, the only first generation therapeutic that has retained efficacy for all of the variants of concern that have emerged. And we’ve retained that efficacy within a relatively small window of potency, while so €“ while we’ve watched all these commercial products dropped off, we have sustained that efficacy and we have continued to move forward. And it’s that historical data that gives us the confidence that we’re likely to move forward under those same exact conditions because it hasn’t mattered whether it’s a parental, virus variant that continues to pick up mutations or it’s a new virus backbone with many more mutations that has been emerging. Another thing I think for people have to keep in mind when they think about the potential sustainability of PolyTope is it’s not just that historical information we rely on, even though we’ve never had to swap to date any of the products out of that combination therapy to retain efficacy.
